Key facts
- iMoon Therapeutics’s last known valuation is $15.5M (Jan 2026).
- It has raised $3.2M; the latest was Early Stage VC ($1.8M) in Jan 2026.
- Notable investors include Remora Biotech.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for iMoon Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for iMoon Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iMoon Therapeutics
Operator of immunotherapy treatments intended to support cancer research and therapy development. The company is currently operating in Stealth mode.
- Sector
- Healthcare
- HQ
- Nantes, France
- Founded
- 2023
- Ownership
- Privately Held (backing)
iMoon Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iMoon Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iMoon Therapeutics in its N-PORT filings yet. We sweep new filings monthly.